{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:41:32Z","timestamp":1774921292770,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10067-022-06305-w","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T19:02:23Z","timestamp":1660676543000},"page":"3661-3673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-5693","authenticated-orcid":false,"given":"Mari","family":"Kihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"13","key":"6305_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMe2002387","volume":"382","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC, Redfield RR (2020) Covid-19\u2014navigating the uncharted. N Engl J Med 382(13):1268\u20131269. https:\/\/doi.org\/10.1056\/NEJMe2002387","journal-title":"N Engl J Med"},{"issue":"5","key":"6305_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39(5):327\u2013346. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.10.002","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"6305_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/BOR.0000000000000786","volume":"33","author":"KM D\u2019Silva","year":"2021","unstructured":"D\u2019Silva KM, Wallace ZS (2021) COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 33(3):255\u2013261. https:\/\/doi.org\/10.1097\/BOR.0000000000000786","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"6305_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, Sawalha AH, Lu Q (2021) COVID-19 and autoimmune diseases. Curr Opin Rheumatol 33(2):155\u2013162. https:\/\/doi.org\/10.1097\/BOR.0000000000000776","journal-title":"Curr Opin Rheumatol"},{"key":"6305_CR5","doi-asserted-by":"publisher","unstructured":"Landew\u00e9 RBM, Kroon FPB, Alunno A et al (2022) EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the rheumatic diseases, annrheumdis-2021\u2013222006. Advance online publication. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222006","DOI":"10.1136\/annrheumdis-2021-222006"},{"issue":"6","key":"6305_CR6","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2665-9913(21)00062-X","volume":"3","author":"CB Nissen","year":"2021","unstructured":"Nissen CB, Sciascia S, de Andrade D et al (2021) The role of antirheumatics in patients with COVID-19. The Lancet Rheumatology 3(6):e447\u2013e459. https:\/\/doi.org\/10.1016\/S2665-9913(21)00062-X","journal-title":"The Lancet Rheumatology"},{"key":"6305_CR7","unstructured":"National Institutes of Health (2022) COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 9 July 2022."},{"issue":"6","key":"6305_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41584-020-0418-0","volume":"16","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Yazdany J (2020) The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol 16(6):293\u2013294. https:\/\/doi.org\/10.1038\/s41584-020-0418-0","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"6305_CR9","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2665-9913(20)30095-3","volume":"2","author":"MA Gianfrancesco","year":"2020","unstructured":"Gianfrancesco MA, Hyrich KL, Gossec L et al (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. The Lancet Rheumatol 2(5):e250\u2013e253. https:\/\/doi.org\/10.1016\/S2665-9913(20)30095-3","journal-title":"The Lancet Rheumatol"},{"issue":"1","key":"6305_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/rheumatology\/keaa483","volume":"60","author":"JW Liew","year":"2021","unstructured":"Liew JW, Bhana S, Costello W et al (2021) The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford) 60(1):353\u2013358. https:\/\/doi.org\/10.1093\/rheumatology\/keaa483","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"6305_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6305_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM et al (2021) Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 80(9):1137\u20131146. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220418","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6305_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219498","journal-title":"Ann Rheum Dis"},{"key":"6305_CR14","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L et al (2022) Coronavirus pandemic (COVID-19). https:\/\/ourworldindata.org\/coronavirus. Accessed 1 March 2022."},{"key":"6305_CR15","unstructured":"Statistics Bureau of Japan, Statistics Handbook of Japan, Ministry of Internal Affairs and Communications, Japan, 2021 (2021) https:\/\/www.stat.go.jp\/english\/data\/handbook\/pdf\/2021all.pdf#page=1. Accessed 1 March 2022."},{"key":"6305_CR16","unstructured":"COVID-19 Global Rheumatology Alliance. Rheumatology COVID-19 Provider-Entered Registry (2020) https:\/\/rheum-covid.org\/downloads\/translations\/English_rheum-covid-provider-registry.pdf. Accessed 1 March 2022."},{"issue":"6","key":"6305_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/rheumatology\/keaa191","volume":"59","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Bhana S, Hausmann JS et al (2020) The rheumatology community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology (Oxford) 59(6):1204\u20131206. https:\/\/doi.org\/10.1093\/rheumatology\/keaa191","journal-title":"Rheumatology (Oxford)"},{"key":"6305_CR18","unstructured":"World Health Organization (2022) Clinical management of COVID-19: Living guideline, 23 June 2022. file:\/\/vmg-vdi-ad04\/redirect(RDS)\/b21200wt\/Downloads\/WHO-2019-nCoV-Clinical-2022.1-eng.pdf Accessed 10 July 2022."},{"issue":"7","key":"6305_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","volume":"79","author":"RB Landew\u00e9","year":"2020","unstructured":"Landew\u00e9 RB, Machado PM, Kroon F et al (2020) EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 79(7):851\u2013858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217877","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6305_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.41437","volume":"72","author":"TR Mikuls","year":"2020","unstructured":"Mikuls TR, Johnson SR, Fraenkel L et al (2020) American College of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis & rheumatology 72(9):e1\u2013e12. https:\/\/doi.org\/10.1002\/art.41437","journal-title":"Arthritis & rheumatology"},{"issue":"11","key":"6305_CR21","doi-asserted-by":"publisher","first-page":"e3677","DOI":"10.1093\/cid\/ciaa1470","volume":"73","author":"N Matsunaga","year":"2021","unstructured":"Matsunaga N, Hayakawa K, Terada M et al (2021) Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan. Clin infectious diseases: an official publ Infectious Diseases Soc America 73(11):e3677\u2013e3689. https:\/\/doi.org\/10.1093\/cid\/ciaa1470","journal-title":"Clin infectious diseases: an official publ Infectious Diseases Soc America"},{"issue":"10223","key":"6305_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"issue":"18","key":"6305_CR23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2002032","journal-title":"N Engl J Med"},{"key":"6305_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.15585\/mmwr.mm6935a4","volume":"69","author":"L Bull-Otterson","year":"2020","unstructured":"Bull-Otterson L, Gray EB, Budnitz DS et al (2020) Hydroxychloroquine and chloroquine prescribing patterns by provider specialty following initial reports of potential benefit for COVID-19 Treatment \u2014 United States, January\u2013June 2020. MMWR Morb Mortal Wkly Rep 69:1210\u20131215. https:\/\/doi.org\/10.15585\/mmwr.mm6935a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6305_CR25","unstructured":"Food and Drug Administration (2020) Revocation of the EUA Letter June 15, https:\/\/www.fda.gov\/media\/138945\/download Accessed 29 April 2022"},{"issue":"3","key":"6305_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"6305_CR27","unstructured":"Pharmaceuticals and Medical Devices Agency (2020) Special approval for emergency of remdesivir for COVID-19. https:\/\/www.pmda.go.jp\/english\/int-activities\/0004.pdf Accessed 1 May 2022."},{"key":"6305_CR28","unstructured":"Ministry of Health, Labour and Welfare (2021) Domestic outbreak trends of new coronavirus infections (in Japanese). 2021. https:\/\/www.mhlw.go.jp\/content\/10906000\/000716059.pdf. Accessed 1 March 2022."},{"issue":"2","key":"6305_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jiac.2021.10.021","volume":"28","author":"H Nomoto","year":"2022","unstructured":"Nomoto H, Suzuki S, Asai Y et al (2022) Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan. J infection chemotherapy: official J Japan Soc Chemotherapy 28(2):224\u2013231. https:\/\/doi.org\/10.1016\/j.jiac.2021.10.021","journal-title":"J infection chemotherapy: official J Japan Soc Chemotherapy"},{"key":"6305_CR30","doi-asserted-by":"publisher","unstructured":"Tanaka E, Inoue E, Abe M et al (2022) Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: results from cross-sectional study in the IORRA cohort. Modern rheumatology, roab120. Advance online publication. https:\/\/doi.org\/10.1093\/mr\/roab120","DOI":"10.1093\/mr\/roab120"},{"key":"6305_CR31","unstructured":"COVID-19 Global Rheumatology Alliance (2020) https:\/\/rheum-covid.org\/. Accessed 1 March 2022."},{"issue":"2","key":"6305_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1620\/tjem.251.87","volume":"251","author":"E Mishima","year":"2020","unstructured":"Mishima E, Anzai N, Miyazaki M et al (2020) Uric acid elevation by favipiravir, an antiviral drug. Tohoku J Exp Med 251(2):87\u201390. https:\/\/doi.org\/10.1620\/tjem.251.87","journal-title":"Tohoku J Exp Med"},{"issue":"8","key":"6305_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/qjmed\/hcaa209","volume":"113","author":"T Sawano","year":"2020","unstructured":"Sawano T, Kotera Y, Ozaki A et al (2020) Underestimation of COVID-19 cases in Japan: an analysis of RT-PCR testing for COVID-19 among 47 prefectures in Japan. QJM: monthly J Assoc Physicians 113(8):551\u2013555. https:\/\/doi.org\/10.1093\/qjmed\/hcaa209","journal-title":"QJM: monthly J Assoc Physicians"},{"issue":"4","key":"6305_CR34","doi-asserted-by":"publisher","first-page":"102778","DOI":"10.1016\/j.autrev.2021.102778","volume":"20","author":"C Xu","year":"2021","unstructured":"Xu C, Yi Z, Cai R et al (2021) Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev 20(4):102778. https:\/\/doi.org\/10.1016\/j.autrev.2021.102778","journal-title":"Autoimmun Rev"},{"issue":"10","key":"6305_CR35","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2665-9913(21)00151-X","volume":"3","author":"YH Shin","year":"2021","unstructured":"Shin YH, Shin JI, Moon SY et al (2021) Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 3(10):e698\u2013e706. https:\/\/doi.org\/10.1016\/S2665-9913(21)00151-X","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"6305_CR36","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/jcm10091844","volume":"10","author":"MDM Ayala Guti\u00e9rrez","year":"2021","unstructured":"Ayala Guti\u00e9rrez MDM, Rubio-Rivas M, Romero G\u00f3mez C et al (2021) Autoimmune diseases and COVID-19 as risk factors for poor outcomes: data on 13,940 hospitalized patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med 10(9):1844. https:\/\/doi.org\/10.3390\/jcm10091844","journal-title":"J Clin Med"},{"issue":"11","key":"6305_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2020-217984","volume":"79","author":"DD Freites Nu\u00f1ez","year":"2020","unstructured":"Freites Nu\u00f1ez DD, Leon L, Mucientes A et al (2020) Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(11):1393\u20131399. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217984","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6305_CR38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00296-021-04803-9","volume":"41","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liu J, Shao R et al (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41(5):851\u2013861. https:\/\/doi.org\/10.1007\/s00296-021-04803-9","journal-title":"Rheumatol Int"},{"issue":"12","key":"6305_CR39","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.41456","volume":"72","author":"RH Haberman","year":"2020","unstructured":"Haberman RH, Castillo R, Chen A et al (2020) COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis & rheumatol (Hoboken, N.J.) 72(12):1981\u20131989. https:\/\/doi.org\/10.1002\/art.41456","journal-title":"Arthritis & rheumatol (Hoboken, N.J.)"},{"issue":"5","key":"6305_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","volume":"51","author":"R Raiker","year":"2021","unstructured":"Raiker R, DeYoung C, Pakhchanian H et al (2021) Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum 51(5):1057\u20131066. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.010","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06305-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T13:09:33Z","timestamp":1668172173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6305"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06305-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK and JA both are employed by Pharmaceuticals and Medical Devices Agency. The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency. TS has received research grants and\/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Asahikasei Pharmaceutical Co., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd. and UCB Japan Co. Ltd. SM received consultant fees\/speakers fees from Asahikasei Pharma Corp., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Astellas Pharma Inc. TN received grant\/research support from Chugai Pharmaceutical Co., Eisai Co., Ltd., Teijin Pharma Ltd., Eli Lilly Japan K.K., Bristol-Myers K.K., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., Ayumi Pharmaceutical Corporation, Shionogi & Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., and Taisho Pharmaceutical Co., Ltd., and consultant fees\/speakers fees from UCB Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Ltd., AbbVie GK., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Kyowa Kirin Co., Ltd., and Mylan N.V. All other co-authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}